Drug Type Biological products |
Synonyms KB-195-Kaleido Biosciences |
Target- |
Mechanism Microbiome modulators |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhasePhase 2 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Hyperammonemia | Phase 2 | - | - | |
Urea Cycle Disorders, Inborn | Preclinical | US | 17 Sep 2019 | |
Urea Cycle Disorders, Inborn | Preclinical | CH | 17 Sep 2019 | |
Urea Cycle Disorders, Inborn | Preclinical | TR | 17 Sep 2019 | |
Urea Cycle Disorders, Inborn | Preclinical | GB | 17 Sep 2019 | |
Urea Cycle Disorders, Inborn | Preclinical | ES | 17 Sep 2019 | |
Urea Cycle Disorders, Inborn | Preclinical | DE | 17 Sep 2019 | |
Urea Cycle Disorders, Inborn | Preclinical | BE | 17 Sep 2019 |